Special Issue "Gene Therapy"
A special issue of Diseases (ISSN 2079-9721).
Deadline for manuscript submissions: closed (31 August 2018)
Dr. Kenneth Lundstrom
PanTherapeutics, Lutry, Switzerland
Interests: viral vectors; gene therapy; immunotherapy; GPCR-based drug discovery; epigenetics
It is my great pleasure to introduce the Special Issue on “Gene Therapy”. In the 1990s, gene therapy was considered most promising and the perfect technology to develop medicines of the future. Inexperience and unfortunate circumstances led to some severe setbacks in conducted clinical trials, which put gene therapy development on hold for some time. Luckily, during this delay much attention was paid to gene therapy vector engineering, improvement of safety standards and refinements in the design of clinical trials, which has contributed to the renaissance of gene therapy. Today, an increasing number of clinical trials are in progress and several gene therapy-based drugs have been approved. It is therefore most appropriate to share the latest development with the scientific community in this special issue. As you will notice, the articles cover engineering of non-viral and viral vectors, gene therapy applications for various indications, such as cancer, hemophilia, AIDS, severe combined immunodeficiency and neurological diseases. Moreover immunotherapy, which has received a lot of attention recently, is presented in detail.
Dr. Kenneth Lundstrom
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 350 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- viral vectors
- non-viral vectors
- disease-based gene therapy